Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Shares Biotechnology ETF offers efficient, diversified exposure to the sector's revival, balancing risk and cost for ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to ...

AbbVie in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the recipient of the AbbVie Biotech Innovators Award, a national prize to help foster ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

Dr. Austin's appointment comes at a transformative period for VERAXA and I’m looking forward to working with him as we enter the next phase in VERAXA’s journey,” commented Christoph Antz, Ph.D., CEO ...

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

These are tough times for the innovation economy in Massachusetts. The challenges include a venture capital funding slump, almost no appetite from stock markets for initial public offerings and a ...

“Despite multiple immunology-based therapeutic approaches currently ... Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies that cover ...